{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Solid+Tumors&page=2", "query": { "condition": "Relapsed/Refractory Solid Tumors", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Solid+Tumors&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T20:36:34.058Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01804634", "title": "Reduced Intensity Haploidentical BMT for High Risk Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory and/or Relapsed Metastatic Solid Tumors" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "low dose total body irradiation", "type": "RADIATION" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "50 Years", "sex": "ALL", "summary": "1 Year to 50 Years" }, "enrollment_count": 60, "start_date": "2013-03-27", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-09-27T20:36:34.058Z", "location_count": 3, "location_summary": "Baltimore, Maryland • The Bronx, New York • Valhalla, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "The Bronx", "state": "New York" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01804634" }, { "nct_id": "NCT00004065", "title": "Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Colorectal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Kidney Cancer", "Leukemia", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Prostate Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-07", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-09-27T20:36:34.058Z", "location_count": 2, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004065" }, { "nct_id": "NCT02680795", "title": "Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Hematological Malignancies" ], "interventions": [ { "name": "Belinostat IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acrotech Biopharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2016-04-27", "completion_date": "2020-07-21", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-27T20:36:34.058Z", "location_count": 3, "location_summary": "Santa Monica, California • Whittier, California • Canton, Ohio", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02680795" }, { "nct_id": "NCT03739931", "title": "Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma", "Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma" ], "interventions": [ { "name": "mRNA-2752", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2018-11-27", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-09-27T20:36:34.058Z", "location_count": 16, "location_summary": "San Francisco, California • Santa Monica, California • Aurora, Colorado + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739931" }, { "nct_id": "NCT01518413", "title": "Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rhabdomyosarcoma and Other Soft Tissue Sarcomas", "Ewing's Sarcoma Family of Tumors", "Osteosarcoma", "Neuroblastoma", "Brain Tumors" ], "interventions": [ { "name": "sorafenib", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HMeany", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "22 Years", "sex": "ALL", "summary": "2 Years to 22 Years" }, "enrollment_count": 17, "start_date": "2011-12", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2015-02-27", "last_synced_at": "2026-09-27T20:36:34.058Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01518413" }, { "nct_id": "NCT03648372", "title": "A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms", "Lymphoma", "Hematologic Neoplasms" ], "interventions": [ { "name": "TAK-981", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2018-10-01", "completion_date": "2023-12-14", "has_results": true, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-09-27T20:36:34.058Z", "location_count": 8, "location_summary": "La Jolla, California • Boston, Massachusetts • Detroit, Michigan + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03648372" }, { "nct_id": "NCT03538028", "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Microsatellite Instability (MSI)-High Endometrial Cancer", "Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])", "Esophageal Cancer", "Hepatocellular Carcinoma", "Melanoma (Uveal Melanoma Excluded)", "Merkel Cell Carcinoma", "Mesothelioma", "MSI-high Colorectal Cancer", "Non-small Cell Lung Cancer (NSCLC)", "Ovarian Cancer", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Small Cell Lung Cancer (SCLC)", "Renal Cell Carcinoma (RCC)", "Triple-negative Breast Cancer", "Urothelial Carcinoma", "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "INCAGN02385", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-06-18", "completion_date": "2020-10-07", "has_results": false, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-09-27T20:36:34.058Z", "location_count": 4, "location_summary": "Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03538028" }, { "nct_id": "NCT01460134", "title": "A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Marginal Zone B Cell Lymphoma)", "Any T-cell Malignancy", "Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma", "Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer", "Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)", "Burkett's Lymphoma", "Primary Lymphoma of the Central Nervous System" ], "interventions": [ { "name": "CDX-1127", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2011-10", "completion_date": "2017-10-16", "has_results": false, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-09-27T20:36:34.058Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01460134" }, { "nct_id": "NCT02793466", "title": "Durvalumab in Pediatric and Adolescent Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Lymphoma", "Central Nervous System Tumors" ], "interventions": [ { "name": "Durvalumab; MEDI4736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leo Mascarenhas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 15, "start_date": "2016-07", "completion_date": "2023-04-30", "has_results": false, "last_update_posted_date": "2023-09-22", "last_synced_at": "2026-09-27T20:36:34.058Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793466" }, { "nct_id": "NCT03635632", "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Neuroblastoma", "Refractory Neuroblastoma", "Relapsed Osteosarcoma", "Relapsed Ewing Sarcoma", "Relapsed Rhabdomyosarcoma", "Uveal Melanoma", "Phyllodes Breast Tumor" ], "interventions": [ { "name": "C7R-GD2.CART cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "74 Years", "sex": "ALL", "summary": "1 Year to 74 Years" }, "enrollment_count": 94, "start_date": "2019-04-23", "completion_date": "2038-05-16", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-27T20:36:34.058Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635632" } ] }